A decade of antiretroviral therapy: A profile of patients with 10 years of highly effective triple therapy;Una década de terapia anti-retroviral: Perfil de pacientes con 10 años de triterapia de alta efectividad

Revista Chilena de Infectologia

Volumn 29, Issue 3, 2012, Pages 337-343

  Wilson, Gonzalo ^a   Wolff, Marcelo ^b  

^a HOSPITAL CARLOS VAN BUREN   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Antiretroviral therapy; Chronic complications; Epidemiology; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ADVERSE EFFECTS; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHILE; CHRONIC DISEASE; COMORBIDITY; DRUG ADMINISTRATION; DYSLIPIDEMIAS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV SURVIVOR; HUMAN; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; SEX RATIO; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILE; CHRONIC DISEASE; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; HIV LONG-TERM SURVIVORS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; SEX RATIO; YOUNG ADULT;

EID: 84864799941     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182012000300015     Document Type: Review

References (11)

1. Dpto. de Epidemiología-DIPLAS-MINSAL" Encuesta Nacional de Salud. Chile 2010.
2. thISHEAD, Toulon. 2008.
3. Wolff M, Cortéz C, Shepherd B E, Beltrán C J; for the Chilean AIDS Cohort Study Group Long term outcomes of a national expanded access program to antiretroviral therapy: The Chilean AIDS Cohort. J Acquir Immune Defic Syndr 2010; 55 (3): 368-74.
4. Kaufmann G R, Khanna N, Weber R, Perrin L, Furrer H, Cavassini M, et al, on behalf of the Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antiviral Ther 2004; 9: 263-74.
5. Greenbaum A H, Wilson L E, Keruly J C, Moore R D, Gebo K A. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008; 22 (17): 2331-9.
6. División de Planificación Sanitaria, Segunda Encuesta de Calidad de Vida y Salud, 2006, MINSAL.
7. Benzie A, Bansi L, Sabin C, Portsmouth S, Hill T, Johnson M, et al on behalf of the United Kingdom Collaborative HIV Cohort (CHIC) Study. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007; 21 (11): 1423-30.
8. Protopopescu C, Marcellin F, Spire B. Healthrelated quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCOCOPILOTE cohort (ANRS CO-8). Qual Life Res 2007; 16: 577-91.
9. Nash D, Kaytal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term inmunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2010; 22 (17): 2291-301.
10. Daar E. Potency and durability of antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34 Supl 2: S111-7.
11. Obrien M, Clark R, Besch C. Patterns and correlates of discontinuation of the initia HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34 (4): 407-14.